HHS' OIG called on the CMS to collect medical-device specific information as part of its claims process, a move that could help the agency quickly identify poorly performing devices.
An AmerisourceBergen Corp. subsidiary pled guilty to illegally distributing misbranded drugs and agreed to pay $260 million for distributing oncology drugs from an unregistered facility.
The doctor will serve nearly 17 years in federal prison and repay $34 million for his part in a $50 million-plus Medicare fraud scheme.
New York paid out an estimated $1.4 billion in Medicaid funds for long-term care providers who didn't follow the state's rules for the program, according to a federal review of the state's Medicaid system.
Novo's settlement sets the precedent that the False Claims Act can be used to punish drug companies that use marketing tactics to avoid drug safety warnings as required by law, experts say.
Federal officials say the settlement resolves allegations that Christus Health and Christus St. Vincent Regional Medical Center made illegal payments in 2001-2009 to county governments for the state's share of Medicaid payments to the hospital.
The home health agencies billed Medicare at an "alarming rate" generally for the most comprehensive physician exam and always adding a prolonged service code, investigators said.
Mylan allegedly misclassified EpiPens as a generic drug, which may have cost the government up to $1.27 billion in lost Medicaid rebates, according to federal estimates.
The 60-year-old Dallas-area doctor and six co-defendants defrauded Medicare and Medicaid out of almost $375 million by certifying 11,000 Medicare beneficiaries through home health providers. Their numbers would have made the doctor's Medicare practice the busiest in the country.
Drugmakers Baxter International and Claris Injectables agreed to divest two pharmaceutical products to settle Federal Trade Commission antitrust concerns over Baxter's proposed $625 million acquisition of Claris' injectable drugs business.
The government doesn't know how much of the $24 billion for premium tax credits was improperly paid and the Government Accountability Office says HHS won't have an estimate until 2022.
The Federal Trade Commission approved the appointment of Quantic Regulatory Services as a monitor in its case alleging that Endo Pharmaceuticals violated antitrust laws by using pay-for-delay settlements to block consumers' access to lower-cost generic versions of Opana ER and Lidoderm.